What is Ozempic?
Ozempic, a medication used to treat type 2 diabetes, is facing global shortages due to its popularity on social media platforms and its potential for weight loss. This injectable drug was developed by the Danish pharmaceutical firm Novo Nordisk. It belongs to a category called GLP-1 agonists. It is still under patent and yet to see its generic versions made.
What does Ozempic do to your body?
Ozempic is found to slow down the rate at which food leaves the stomach, thereby reducing appetite. Peer-reviewed research found that nearly three-quarters of users lost over 10% of their body weight after taking this drug. This property led Ozempic to become a widely used weight-loss-inducing drug.
What happens when you stop taking Ozempic?
People start to put on weight as they stop taking the drug. This is because of the ingredient called “SEMAGLUTIDE” in the drug. The semaglutide helps the pancreas in releasing the right amount of insulin. The main role of the pancreas is to maintain sugar levels in the blood. It produces insulin and other hormones. When Pancreas does not produce the right amount of insulin in the body, diabetes occurs.
What are GLP-1 agonists?
The Ozempic is a GLP-1 agonist drug. They are a class of drugs used to treat type-2 diabetes. GLP-1 drugs have three main functions. They are stimulating insulin production, slow down insulin absorption, and inhibit glucagon release. There are two types of drugs namely agonist drugs and antagonist drugs. The agonist drugs bind to the receptors of the cell and activate the target. The antagonist drugs bind to the target and stop the actions of other substances.
What is Ozempic Controversy?
The FDA has only approved Ozempic to treat diabetes. However, people are now using it for weight loss. But when consumed by a non-diabetic person, it may lead to side effects such as constipation, stomach pain, and vomiting. Though the side effects are very less, in the long term they cause serious problems.
Month: Current Affairs - March, 2023
Category: Economy & Banking Current Affairs